163 related articles for article (PubMed ID: 19351766)
1. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
2. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
3. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
4. RhoGDI2 as a therapeutic target in cancer.
Cho HJ; Baek KE; Yoo J
Expert Opin Ther Targets; 2010 Jan; 14(1):67-75. PubMed ID: 20001211
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.
Theodorescu D; Sapinoso LM; Conaway MR; Oxford G; Hampton GM; Frierson HF
Clin Cancer Res; 2004 Jun; 10(11):3800-6. PubMed ID: 15173088
[TBL] [Abstract][Full Text] [Related]
6. PLCĪ³ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Cho HJ; Baek KE; Nam IK; Park SM; Kim IK; Park SH; Im MJ; Ryu KJ; Yoo JM; Hong SC; Kim JW; Lee CW; Yoo J
Biochem Biophys Res Commun; 2011 Oct; 414(3):575-80. PubMed ID: 21986528
[TBL] [Abstract][Full Text] [Related]
7. Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.
Cho HJ; Baek KE; Kim IK; Park SM; Choi YL; Nam IK; Park SH; Im MJ; Yoo JM; Ryu KJ; Oh YT; Hong SC; Kwon OH; Kim JW; Lee CW; Yoo J
J Proteome Res; 2012 Apr; 11(4):2355-64. PubMed ID: 22364609
[TBL] [Abstract][Full Text] [Related]
8. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.
Gildea JJ; Seraj MJ; Oxford G; Harding MA; Hampton GM; Moskaluk CA; Frierson HF; Conaway MR; Theodorescu D
Cancer Res; 2002 Nov; 62(22):6418-23. PubMed ID: 12438227
[TBL] [Abstract][Full Text] [Related]
9. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis.
Hu LD; Zou HF; Zhan SX; Cao KM
Oncol Rep; 2007 Jun; 17(6):1383-9. PubMed ID: 17487395
[TBL] [Abstract][Full Text] [Related]
10. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity.
Wang YW; Qu Y; Li JF; Chen XH; Liu BY; Gu QL; Zhu ZG
Clin Cancer Res; 2006 Aug; 12(16):4965-73. PubMed ID: 16914586
[TBL] [Abstract][Full Text] [Related]
12. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.
Titus B; Frierson HF; Conaway M; Ching K; Guise T; Chirgwin J; Hampton G; Theodorescu D
Cancer Res; 2005 Aug; 65(16):7320-7. PubMed ID: 16103083
[TBL] [Abstract][Full Text] [Related]
13. [Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation].
Cai SR; Chen CQ; Wang Z; He YL; Cui J; Wu WH; Wu H; Zhan WH
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(33):2326-30. PubMed ID: 19087692
[TBL] [Abstract][Full Text] [Related]
14. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation.
Harding MA; Theodorescu D
Urol Oncol; 2007; 25(5):401-6. PubMed ID: 17826660
[TBL] [Abstract][Full Text] [Related]
15. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.
Yi B; Hu Y; Qin G; Gu W; Zhu X; He S; Zhou J; Li D
Int J Mol Med; 2014 Jul; 34(1):205-12. PubMed ID: 24788627
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis.
Niu H; Li H; Xu C; He P
Oncol Rep; 2010 Aug; 24(2):465-71. PubMed ID: 20596634
[TBL] [Abstract][Full Text] [Related]
17. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Wang Z; Cai SR; He YL; Zhan WH; Chen CQ; Cui J; Wu WH; Wu H; Song W; Zhang CH; Peng JJ; Huang XH
Ann Surg Oncol; 2009 Jan; 16(1):208-19. PubMed ID: 19009246
[TBL] [Abstract][Full Text] [Related]
18. Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Matsukawa Y; Semba S; Kato H; Koma Y; Yanagihara K; Yokozaki H
Pathobiology; 2010; 77(3):155-62. PubMed ID: 20516731
[TBL] [Abstract][Full Text] [Related]
19. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness.
Zhang Y; Zhang B
Cancer Res; 2006 Jun; 66(11):5592-8. PubMed ID: 16740694
[TBL] [Abstract][Full Text] [Related]
20. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment.
Kuroda T; Kitadai Y; Tanaka S; Yang X; Mukaida N; Yoshihara M; Chayama K
Clin Cancer Res; 2005 Nov; 11(21):7629-36. PubMed ID: 16278381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
